ReviewEuropean journal of nuclear medicine and molecular imaging2021
Clinical validity of increased cortical uptake of [
Review in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Blood-based biomarkers and early diagnosis of Alzheimer's disease.Neural regeneration research · 2026Article
- Explainable Machine Learning Reveals Time-Dependent Cognitive Risk in Minor Neurocognitive Disorder: Implications for Health Promotion and Early Risk Stratification.Biomedicines · 2026Article
- Mapping individual molecular connectomes in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers.European journal of clinical investigation · 2026Review
- Advances in PET imaging of protein aggregates associated with neurodegenerative disease.Nature reviews. Neurology · 2025Review
- The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study.Alzheimer's research & therapy · 2024Article
- Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers.Molecules (Basel, Switzerland) · 2024Review
- Stricker Learning Span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and tau PET-defined biomarker groups as in-person Auditory Verbal Learning Test.Journal of the International Neuropsychological Society : JINS · 2024Article
- Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.Annals of nuclear medicine · 2023Article
- Unsupervised [European journal of nuclear medicine and molecular imaging · 2023Article
- Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [Alzheimer's research & therapy · 2023Article
- Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study.Alzheimer's research & therapy · 2023Article
- Deep Learning for Brain MRI Confirms Patterned Pathological Progression in Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The Early Diagnosis of Alzheimer's Disease: A Patient-Centred Conversation with the Care Team.Neurology and therapy · 2023Article
- Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.Nature medicine · 2022Article
- Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation.Medicina (Kaunas, Lithuania) · 2022Review
- International consensus on the use of tau PET imaging agentEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework.Journal of Alzheimer's disease : JAD · 2022Article
- Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn 2017, the Geneva Alzheimer's disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological diagnostic biomarkers to AD biomarkers, with the aim to accelerate their development and implementation in clinical practice. With this work, we assess the maturity of [
methodsThe level of maturity of [
resultsThe main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. [
conclusionCurrent literature provides partial evidence for clinical utility of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.